Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Small-Molecule Drug Start-Ups

This article was originally published in Start Up

Executive Summary

Companies pursuing small-molecule drugs are by far the most popular of the start-ups in biopharmaceuticals. But the biggest opportunity in the business is still up for grabs: the industrialization of medicinal chemistry.

You may also be interested in...



Small Molecule Therapeutics Inc.

Small Molecule Therapeutics uses proprietary screening technologies to develop leads--in areas including anti-infectives, diabetes, immunology and hematopoiesis--which can be partnered with large pharmaceutical companies.

AtheroGenics Inc.

Atherogenics Inc. has begun clinical trials on a compound that goes to the heart of the matter by attacking the inflammation processes that can cause atherosclerosis and the build-up of plaque.

Kinetix Pharmaceuticals Inc.

Kinetix Pharmaceuticals is a small molecule drug discovery company developing protein kinase inhibitors for four major therapuetic areas: immunosuppression/autoimmunity, asthma/allergy and inflammation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel